https://doi.org/10.4081/ejtm.2020.8970
Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine
Submitted: 19 March 2020
Accepted: 13 May 2020
Published: 4 August 2020
Accepted: 13 May 2020
Abstract Views: 934
PDF: 542
HTML: 10
HTML: 10
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Tumorigenesis is a multiphasic process in which genetic alterations guide the progressive transformation in cancer cells1. In order to evaluate the possible correlation between some gene variants and the risk of the toxicity development onset, two of the polymorphisms of the thymidylate synthase (TYMS), rs34743033 (2R/3R) and rs16430 (DEL/INS) were investigated. We enrolled in our study 47 patients from the Hospital of Sicily. Our preliminary findings suggest that there could be a linkage between the genotypes discussed and the development of the toxicity following the chemotherapy treatment. These results need to be confirmed by further studies, however this short paper offers some initial insight into the relationships between genetic background and the better outcome for patients.
Pradeepkiran JA, Sainath SB, Kumar KK, Balasubramanyam L, Prabhakar KV, Bhaskar M. CGMD: un database integrato di geni e marcatori del cancro. Rep . Sci . 2015; 5: 12035. Pubblicato 2015 Lug 10. doi: 10.1038 / srep12035
DOI: https://doi.org/10.1038/srep12035
Ebadi MR, Aghdam MK, Lima ZS, Younesi L. Investigation into breast cancer and partial breast reconstruction: A review. Eur J Transl Myol. 2019 May 16;29(2):8157. doi: 10.4081/ejtm.2019.8157. eCollection 2019 May 7.
DOI: https://doi.org/10.4081/ejtm.2019.8157
Bloomfield M, Duesberg P. Inherent variability of cancer-specific aneuploidy generates metastases. Mol Cytogenet. 2016;9:90. Published 2016 Dec 16. doi:10.1186/s13039-016-0297-x
DOI: https://doi.org/10.1186/s13039-016-0297-x
Abbasi A, Heydari S. Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer. Eur J Transl Myol. 2018 Jun 4;28(2):7423. doi: 10.4081/ejtm.2018.7423. eCollection 2018 Apr 24.
DOI: https://doi.org/10.4081/ejtm.2018.7423
Dunford A, Weinstock DM, Savova V, et al. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017;49(1):10‐16. doi:10.1038/ng.3726
DOI: https://doi.org/10.1038/ng.3726
Galvan A, Ioannidis JP, Dragani TA. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet 2010; 26(3):132-41.
DOI: https://doi.org/10.1016/j.tig.2009.12.008
Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000; 9:1381-5.
Guan X, Liu H, Ju J, et al. Brewster AM, Buchholz TA, Arun BK, Wei Q, and Liu Z, Genetic Variant rs16430 6bp > 0bp at the microRNA-Binding Site in TYMS and Risk of Sporadic Breast Cancer Risk in Non-Hispanic White Women Aged ≤55 Years. Mol Carcinog 2015; 54(4): 281-90
DOI: https://doi.org/10.1002/mc.22097
Vilmos A, Hitre E, Köves I, et al. Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients. Int J Cancer 2005; 108(6): 852-6.
Chu, E., Callender, M. A., Farrell, M. P., & Schmitz, J. C. (2003). Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer chemotherapy and pharmacology, 52(1), 80-89.
DOI: https://doi.org/10.1007/s00280-003-0625-9
Pellicer, M., García-González, X., García, M. I., Robles, L., Grávalos, C., García-Alfonso, P. and Iglesias, I. (2017). Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacological research, 120, 133-137.
DOI: https://doi.org/10.1016/j.phrs.2017.03.021
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer (Phila) 1981;47:207–14.
DOI: https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
How to Cite
Vitello, S., Di Liegro, I., Ricciardi, M. R., Verga, C., Amato, A., Schiera, G., Di Liegro, C., Messina, G., & Proia, P. (2020). Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine. European Journal of Translational Myology, 30(3). https://doi.org/10.4081/ejtm.2020.8970
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.